Summary.-Fragments of human renal carcinoma tissue have been co-cultured with mouse calvaria. In 9/13 cases significant bone resorption occurred whilst in no case did control kidney cause significant resorption. When bone resorption did occur, it could be reduced by inclusion of indomethacin in the culture medium. In some cases when theophylline was included in culture medium to prevent cyclic AMP breakdown, there was enhancement of tumour-induced bone resorption. Control studies without tumour showed that none of the experimental treatments had a direct effect on bone. Radioimmunoassay of prostaglandin E (PGE) levels in pooled culture media showed that tumour fragments produced appreciable amounts of PGE, and that this production was lowered by indomethacin and increased by theophylline. It is concluded that the bone resorption induced by these tumours is due to a prostaglandin, and that prostaglandin production may be controlled by changes in cyclic AMP metabolism.
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ADVERSE metabolic effects are frequently associated with both primary and metastatic neoplastic disease, often due to the production by the tumour of a humoral agent (Rees, 1976) . Amongst these effects is hypercalcaemia due to the production by neoplastic tissue of boneresorbing agents, especially when the tumour readily metastasizes to bone.
In the case of renal carcinoma there is a known incidence of hypercalcaemia and also a propensity of the tumour to metastasize to bone (Heath, 1976) . Previously it has been shown that the hypercalcaemia may be associated with ectopic parathyroid hormone (PTH) production (Greenberg, Martin and Sutcliffe, 1973) or with prostaglandin (PG) production (Brereton et al., 1974; Robertson et al., 1975) .
This paper demonstrates the production of bone-resorbing activity by unselected renal carcinomas in tissue culture, and presents evidence that a PG may be a major causative agent.
MATERIALS AND METHODS
Materials. BGJ culture medium (Biggers, Gwatkin and Heynor, 1961) was prepared as a powder. The final solution was suppleniented with antibiotics, an antifungal agent, ascorbic acid (150 ,ug/ml) and 15% heated horse serum as described previously (Webster, Atkins and Peacock, 1974).
The PTH used was partially purified bovine hormone with a potency of 1000 u/mg (Moseley et al., 1975) Methods.-The bone culture method has been described in detail elsewhere (Webster et al., 1974) . Briefly, calvaria were explanted and equilibrated in bulk in 40 ml culture medium for 12-24 h at 37°C in an atmosphere of 5% CO2 in air. After the equilibration period, calvaria were transferred to small culture dishes containing 2 ml of medium. Incubations were then continued for 3 days, at the end of which time the calcium level in the medium was measured by automatic titration using a Corning Model 503 Calcium Analyser.
In co-culture experiments calvaria were placed on the stainless steel grid as usual and surrounded by 4 1-mm3 explants of control or tumour renal tissue. Care was taken to ensure that there was no direct contact between the bone and other tissues. Viability of the explanted renal tissue was assessed by histological examination of the tissue before and after culture. Tissue morphology was preserved with little overt evidence of cell death, thus minimizing the possibility that bone resorption might be produced by components of disintegrating cells.
In experiments where 1,25-(OH)2D3, PGE2, theophylline or indomethacin were added to culture media, they were dissolved in a small amount of ethanol and added to the medium to give a level of not more than 0-4% ethanol.
This level of ethanol has been shown previously not to affect the response of bone to PTH (Atkins et al., 1972) . Results were expressed as the release of ,umol calcium during the 3-day incubation period. Differences were assessed by means of Student's t test; values of P < 0-05 were assumed to be significant. PGE levels were assessed by radioimmunoassay after extraction and purification of pooled media on columns of silicic acid (Hillier and Dilley, 1974) . Recovery of added 3H-PGE2 was 53-6 ± 2-2% (n = 29). The antiserum used did not distinguish between PGE1 and PGE2, and levels are therefore expressed as total PGE (ng/ml) corrected for recovery after silicic acid chromatography. PTH levels were measured by radioimmunoassay (Melick and Martin, 1968 ) using antiserum BW 211/32 (Burroughs Wellcome) and highly purified bovine PTH for labelling and as standard, and cyclic AMP levels were assessed by a specific protein-binding assay (Brown et al., 1971) .
RESULTS

Control experiments
In order to identify the nature of any bone-resorbing factors produced by tumours, it was necessary to ensure that pharmacological manipulation of the system had effects on tumour cells rather than on bone tissue. The effects of PTH in this bone culture system are well known (Webster et al., 1974) and PTHinduced bone resorption can be prevented by a variety of physiological and pharmacological agents (Atkins and Peacock, 1975) . Many of these inhibitors also inhibit bone resorption induced by other agents such as 1,25-(OH)2D3 (D. Atkins, unpublished observations). Fig. 1 . shows that PGE2 is a potent bone-resorbing agent, the minimum effective dose being 10 ng/ml. Table I shows that bone resorption, however induced, was not inhibited by concentrations of indomethacin which are reported to inhibit prostaglandin biosynthesis (Flower, 1974) .
Another sudy has shown (Martin et al., 1976 ) that membrane adenylate cyclase activity is elevated in renal cortical carcinoma. An attempt was therefore made to reduce adenosine-3',5'-cyclic monophosphate (cyclic AMP) hydrolysis by including a phosphodiesterase (PDE) inhibitor (theophylline) in culture media. Levels of theophylline generally used to inhibit PDE (10 mM) are toxic to bone (J. N. M. Heersche, personal communication). However, lower levels (up to 2 mM) did not stimulate bone resorption, nor did they modify the responsiveness to PTH (Table II) . At the higher dose levels there Results expressed as the mean difference ± s.e. from the control group. There were 10 calvaria/group. The P values give the significance of the difference from the control group; NS = not significant. was a tendency towards net calcium uptake.
These preliminary observations allowed more meaningful conclusions to be drawn from the subsequent co-culture studies.
Co-culture experiments
The bone-resorbing activity of several renal cortical carcinomas is shown in Table III . In each experiment the boneresorbing activity associated with tumour explants was compared with that of a maximally effective concentration of PTH (1 u/ml) and normalized to a constant PTH effect of 1-5 ,tmol calcium released in 3 days. Nine of the 13 tumours caused significant bone resorption, whilst none of the control renal tissue samples were effective.
Cyclic AMP levels in pooled media were less than 2 pmol/ml, even when theophylline was included in incubations, and immunoreactive PTH levels were less than 1 ng/ml in all experiments.
In several cases the possibility that a prostaglandin might have caused bone resorption was investigated by including indomethacin (14 /tM) in the culture medium. Table III Table IV . A typical example is shown in Fig. 2 . This was not due to a direct action of cyclic AMP upon bone, since no detectable cyclic nucleotide was found in pooled culture media. Fig. 2 (top) shows the PGE level in pooled culture medium from the same experiment. (Lee and Attallah, 1975 ) and 1,25-(OH)2D3 (Lawson et al., 1971 ) are produced in normal kidney, and there is an inicidence, of uinknown frequency, of secretion of PTH by renal cortical carcinoma (Buckle, McMillan anid Mallinson, 1970; Greenberg et al., 1973 writh hypercalcaemia (Benson et al., 1974) it has beeni exclutded as a causative agent in many other hyperealcaemic patients free from skeletal metastases (Powell et al., 1973) . Although cyclie AMP is involved in the action of PTH on bone (Chase and Autrbach, 1970) Prostaglandins are potenlt bone-resorbitg agents in vitro (Klein and Raisz, 1970) and are associated, probably as causative agents, with hypercalcaemia of malignancy (Tashjian et al., 1972; Powles et al., 1973; Bennett et al., 1975; Dowsett et al., 1976) . Two stuidies have implicated PGs in the development of hypercalcaemia associated with renal cortical carcinoma (Brereton et al., 1974; Robertsoii et al., 605 1975) . Evidence that a PG was a cause of bone resorption in these co-cultured renal carcinomas comes from the observation that, to a varying degree, indomethacin inhibited tumour-induced bone resorption. Furthermore, indomethacin had no effect on bone per se or on the response of bone to other humoral resorbing agents. In all cases where medium PGE levels were measured, media from tumour incubations had increased PGE levels which were lowered by indomethacin treatment. Although the data strongly suggest that bone resorption was due to the production of PGE, the levels of PG found in culture media were lower than those needed to obtain substantial bone resorption. However, if metabolism of PGE occurs in the culture system, the total amount of PGE secreted during the 3-day incubation period may not be accurately represented by the final concentration. Recently it has been shown in both man and experimental animals that the development of hypercalcaemia correlates better with PG metabolite levels in plasma and urine (Tashjian, Koelkel and Levine, 1977b, Seyberth et al., 1975) . Studies are in progress to measure PGE levels at earlier times and also the levels of PGE metabolites. Alternatively, it may well be that PGE does not account for all the bone-resorbing activity.
Theophylline enhanced tumour-induced bone resorption and increased PGE levels in culture media. We suggest that this may be due, in part, to theophylline reducing cyclic AMP hydrolysis, in the face of a high rate of cyclic AMP production due to increased membrane adenylate cyclase activity (Martin et al., 1976) . Jaffe (1974) has previously suggested that cyclic AMP may enhance PG production by tumour cells.
It must be stressed that none of our patients had any overt disorders of calcium metabolism. Thus this study demonstrates only the potential for the production of bone-resorbing factors by renal cortical carcinomas. However, Bennett et al. (1975) showed that patients with breast cancer who produced the largest amounts of PGs were the most likely to form bony metastases. In addition, Galasko and Bennett (1976) showed that when the VX2 carcinoma was injected into indomethacin-treated rabbits the number of bone deposits was reduced. The present series of renal cortical tumours has not been followed long enough to attempt to relate the above observations to our own.
Although these studies indicate the ability of renal cortical tumours to produce prostaglandins as bone-resorbing agents, the existence of other factors with similar effects cannot be excluded. In view of the rapid metabolism of PGE to metabolites which are less effective on bone (Atkins and Martin, 1977; Raisz et al., 1977; Tashjian, Tice and Sides, 1977a) it may be that PGE production by renal cortical carcinoma is a major factor in causing hypercalcaemia only when tumour has metastasized to bone, or is present as massive non-bony deposits. 
